These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 16107195)

  • 1. Peginterferon-alpha2a (40 kDa) (Pegasys) for hepatitis B.
    Hui CK; Lau GK
    Expert Rev Anti Infect Ther; 2005 Aug; 3(4):495-504. PubMed ID: 16107195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegylated interferon alpha-2a (40 kDa) in the treatment of chronic hepatitis B.
    Lai L; Hui CK; Leung N; Lau GK
    Int J Nanomedicine; 2006; 1(3):255-62. PubMed ID: 17717966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peginterferon-alpha 2a for the treatment of hepatitis B infection.
    Cooksley WG
    Expert Opin Pharmacother; 2005 Jul; 6(8):1373-80. PubMed ID: 16013986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.
    Marcellin P; Lau GK; Bonino F; Farci P; Hadziyannis S; Jin R; Lu ZM; Piratvisuth T; Germanidis G; Yurdaydin C; Diago M; Gurel S; Lai MY; Button P; Pluck N;
    N Engl J Med; 2004 Sep; 351(12):1206-17. PubMed ID: 15371578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
    Lau GK; Piratvisuth T; Luo KX; Marcellin P; Thongsawat S; Cooksley G; Gane E; Fried MW; Chow WC; Paik SW; Chang WY; Berg T; Flisiak R; McCloud P; Pluck N;
    N Engl J Med; 2005 Jun; 352(26):2682-95. PubMed ID: 15987917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B.
    Bonino F; Marcellin P; Lau GK; Hadziyannis S; Jin R; Piratvisuth T; Germanidis G; Yurdaydin C; Diago M; Gurel S; Lai MY; Brunetto MR; Farci P; Popescu M; McCloud P;
    Gut; 2007 May; 56(5):699-705. PubMed ID: 17127704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic hepatitis B: a wider range of therapeutic options.
    Prescrire Int; 2007 Aug; 16(90):157-62. PubMed ID: 17724844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of peginterferon alpha-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom.
    Veenstra DL; Sullivan SD; Dusheiko GM; Jacobs M; Aledort JE; Lewis G; Patel KK
    Eur J Gastroenterol Hepatol; 2007 Aug; 19(8):631-8. PubMed ID: 17625431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New and emerging treatment of chronic hepatitis B.
    Keeffe EB; Marcellin P
    Clin Gastroenterol Hepatol; 2007 Mar; 5(3):285-94. PubMed ID: 17218162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B.
    Gish RG; Lau DT; Schmid P; Perrillo R
    Am J Gastroenterol; 2007 Dec; 102(12):2718-23. PubMed ID: 17662102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural course, therapeutic options and economic evaluation of therapies for chronic hepatitis B.
    Han SH
    Drugs; 2006; 66(14):1831-51. PubMed ID: 17040114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral treatment for chronic hepatitis B virus infection--immune modulation or viral suppression?
    Buster EH; Janssen HL
    Neth J Med; 2006 Jun; 64(6):175-85. PubMed ID: 16788215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of chronic hepatitis B infection using interferon.
    Guan R
    Med J Malaysia; 2005 Jul; 60 Suppl B():28-33. PubMed ID: 16108170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B.
    Chan HL; Hui AY; Wong VW; Chim AM; Wong ML; Sung JJ
    Hepatology; 2005 Jun; 41(6):1357-64. PubMed ID: 15880608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peginterferon-alpha-2a (40kD): a review of its use in the management of patients with chronic hepatitis B.
    Robins GW; Scott LJ; Keating GM
    Drugs; 2005; 65(6):809-25. PubMed ID: 15819595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of peginterferon alpha-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan.
    Sullivan SD; Veenstra DL; Chen PJ; Chang TT; Chuang WL; Tsai C; Patel K
    J Gastroenterol Hepatol; 2007 Sep; 22(9):1494-9. PubMed ID: 17716353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Recent developments in the treatment of chronic hepatitis B and C].
    Chamuleau RA
    Ned Tijdschr Tandheelkd; 2007 Aug; 114(8):353-6. PubMed ID: 17822245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peginterferon alfa-2a in patients with chronic hepatitis C.
    Zeuzem S; Feinman SV; Rasenack J; Heathcote EJ; Lai MY; Gane E; O'Grady J; Reichen J; Diago M; Lin A; Hoffman J; Brunda MJ
    N Engl J Med; 2000 Dec; 343(23):1666-72. PubMed ID: 11106715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of antiviral effect of lamivudine with interferon-alpha2a versus -alpha2b in children with chronic hepatitis B infection.
    Ozgenc F; Dikici B; Targan S; Doganci T; Akman S; Aydogdu S; Yagci RV
    Antivir Ther; 2004 Feb; 9(1):23-6. PubMed ID: 15040533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response.
    Chan HL; Wong VW; Tse AM; Tse CH; Chim AM; Chan HY; Wong GL; Sung JJ
    Clin Gastroenterol Hepatol; 2007 Dec; 5(12):1462-8. PubMed ID: 18054753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.